Duopharma posts higher Q1 net profit, vaccine deal to boost FY21 earnings 

KUALA LUMPUR: Duopharma Biotech Bhd said earnings climbed in the first quarter of stronger demand for healthcare products.

Net profit rose 30% to RM17.6mil from RM13.56mil a year ago. Revenue improved 5% to RM166mil.

The company, which has a deal to supply Sputnik V vaccine to the government, is also proposing to issue bonus shares on the basis of one free share for every three shares held at a date to be determined later.

"Pending the execution and signing of definitive supply agreements and conditional approval by the Drug Control Authority, the management of vaccine supply is expected to contribute positively to the future earnings of Duopharma Group for the financial nyear ending Dec 31, 2021," it said.

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 46
Cxense type: free
User access status: 3

Duopharma Biotech , vaccine , Sputnix V


Next In Business News

Palm oil prices rally to a new high, benchmark above RM4,400 a tonne
Serba Dinamik to list on Nasdaq via Data Knights
Careplus posts strong Q1 results, says glove prices may have peaked
Ringgit closes higher vs US dollar
M3 Technologies board rebuts shareholders’ claims
Copper jumps to record as growth bets supercharge commodities
Bursa Securities freezes upper limit price for Widetech
Gloves give KLCI much needed lift as Covid cases climb
MSC Q1 profit climbs as tin prices reach ten-year high
BSN to implement BPR 2021 Phase 2 payments

Stories You'll Enjoy